Intratumoral administration of 5-[123I]iodo-2′ deoxyuridine in a patient with a brain tumor

Amin I. Kassis, Sabah S. Tumeh, Patrick Y.C. Wen, Janina Baranowska-Kortylewicz, Annick D. Van Den Abbeele, Robert E. Zimmerman, Paulo A. Carvalho, Basem M. Garada, William C. DeSisto, Nancy Olsen Bailey, Frank P. Castronovo, Giuliano Mariani, Peter Mc L. Black, S. James Adelstein

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

We have initiated a study in which patients suspected of having primary gliomas are given a single intracerebral injection of the thymidine analog 5-[123I]iodo-2′-deoxyuridine ([123I]IUdR). The purpose of the study is to determine the biodistribution of the radiopharmaceutical and to calculate dose estimates to the tumor and normal tissues. Methods: A patient with a cystic glioma was injected with [123I]IUdR. Whole-body scans and brain scans were obtained at various times after injection, and blood, urine and stools were collected and assayed for radioactivity to assess its biodistribution and clearance. Results: Scintigraphic imaging demonstrated that the distribution of radiolabeled IUdR was mainly confined to the tumor (injection site), stomach and bladder. Disappearance from the tumor site and blood clearance were delayed probably due to collection in the cystic lesion. Eighty percent of the injected dose was recovered in the urine. Conclusion: The pharmacokinetics of [123I]IUdR locoregionally administered to a human glioma in situ resembled those observed in a rat glioma model where administration of the radiopharmaceutical radiolabeled with the Auger electron emitter 125I was therapeutically effective.

Original languageEnglish (US)
Pages (from-to)19S-22S
JournalJournal of Nuclear Medicine
Volume37
Issue number4 SUPPL.
StatePublished - Apr 1 1996

Fingerprint

Idoxuridine
Deoxyuridine
Brain Neoplasms
Glioma
Radiopharmaceuticals
Injections
Urine
Whole Body Imaging
Neoplasms
Thymidine
Radioactivity
Stomach
Urinary Bladder
Pharmacokinetics
Electrons
Brain

Keywords

  • Central nervous system tumors
  • Intratumoral injection
  • Iodine-123-IUdR

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Kassis, A. I., Tumeh, S. S., Wen, P. Y. C., Baranowska-Kortylewicz, J., Van Den Abbeele, A. D., Zimmerman, R. E., ... Adelstein, S. J. (1996). Intratumoral administration of 5-[123I]iodo-2′ deoxyuridine in a patient with a brain tumor. Journal of Nuclear Medicine, 37(4 SUPPL.), 19S-22S.

Intratumoral administration of 5-[123I]iodo-2′ deoxyuridine in a patient with a brain tumor. / Kassis, Amin I.; Tumeh, Sabah S.; Wen, Patrick Y.C.; Baranowska-Kortylewicz, Janina; Van Den Abbeele, Annick D.; Zimmerman, Robert E.; Carvalho, Paulo A.; Garada, Basem M.; DeSisto, William C.; Bailey, Nancy Olsen; Castronovo, Frank P.; Mariani, Giuliano; Black, Peter Mc L.; Adelstein, S. James.

In: Journal of Nuclear Medicine, Vol. 37, No. 4 SUPPL., 01.04.1996, p. 19S-22S.

Research output: Contribution to journalArticle

Kassis, AI, Tumeh, SS, Wen, PYC, Baranowska-Kortylewicz, J, Van Den Abbeele, AD, Zimmerman, RE, Carvalho, PA, Garada, BM, DeSisto, WC, Bailey, NO, Castronovo, FP, Mariani, G, Black, PML & Adelstein, SJ 1996, 'Intratumoral administration of 5-[123I]iodo-2′ deoxyuridine in a patient with a brain tumor', Journal of Nuclear Medicine, vol. 37, no. 4 SUPPL., pp. 19S-22S.
Kassis AI, Tumeh SS, Wen PYC, Baranowska-Kortylewicz J, Van Den Abbeele AD, Zimmerman RE et al. Intratumoral administration of 5-[123I]iodo-2′ deoxyuridine in a patient with a brain tumor. Journal of Nuclear Medicine. 1996 Apr 1;37(4 SUPPL.):19S-22S.
Kassis, Amin I. ; Tumeh, Sabah S. ; Wen, Patrick Y.C. ; Baranowska-Kortylewicz, Janina ; Van Den Abbeele, Annick D. ; Zimmerman, Robert E. ; Carvalho, Paulo A. ; Garada, Basem M. ; DeSisto, William C. ; Bailey, Nancy Olsen ; Castronovo, Frank P. ; Mariani, Giuliano ; Black, Peter Mc L. ; Adelstein, S. James. / Intratumoral administration of 5-[123I]iodo-2′ deoxyuridine in a patient with a brain tumor. In: Journal of Nuclear Medicine. 1996 ; Vol. 37, No. 4 SUPPL. pp. 19S-22S.
@article{3f90e659ea4749c5834140c15f87a185,
title = "Intratumoral administration of 5-[123I]iodo-2′ deoxyuridine in a patient with a brain tumor",
abstract = "We have initiated a study in which patients suspected of having primary gliomas are given a single intracerebral injection of the thymidine analog 5-[123I]iodo-2′-deoxyuridine ([123I]IUdR). The purpose of the study is to determine the biodistribution of the radiopharmaceutical and to calculate dose estimates to the tumor and normal tissues. Methods: A patient with a cystic glioma was injected with [123I]IUdR. Whole-body scans and brain scans were obtained at various times after injection, and blood, urine and stools were collected and assayed for radioactivity to assess its biodistribution and clearance. Results: Scintigraphic imaging demonstrated that the distribution of radiolabeled IUdR was mainly confined to the tumor (injection site), stomach and bladder. Disappearance from the tumor site and blood clearance were delayed probably due to collection in the cystic lesion. Eighty percent of the injected dose was recovered in the urine. Conclusion: The pharmacokinetics of [123I]IUdR locoregionally administered to a human glioma in situ resembled those observed in a rat glioma model where administration of the radiopharmaceutical radiolabeled with the Auger electron emitter 125I was therapeutically effective.",
keywords = "Central nervous system tumors, Intratumoral injection, Iodine-123-IUdR",
author = "Kassis, {Amin I.} and Tumeh, {Sabah S.} and Wen, {Patrick Y.C.} and Janina Baranowska-Kortylewicz and {Van Den Abbeele}, {Annick D.} and Zimmerman, {Robert E.} and Carvalho, {Paulo A.} and Garada, {Basem M.} and DeSisto, {William C.} and Bailey, {Nancy Olsen} and Castronovo, {Frank P.} and Giuliano Mariani and Black, {Peter Mc L.} and Adelstein, {S. James}",
year = "1996",
month = "4",
day = "1",
language = "English (US)",
volume = "37",
pages = "19S--22S",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Intratumoral administration of 5-[123I]iodo-2′ deoxyuridine in a patient with a brain tumor

AU - Kassis, Amin I.

AU - Tumeh, Sabah S.

AU - Wen, Patrick Y.C.

AU - Baranowska-Kortylewicz, Janina

AU - Van Den Abbeele, Annick D.

AU - Zimmerman, Robert E.

AU - Carvalho, Paulo A.

AU - Garada, Basem M.

AU - DeSisto, William C.

AU - Bailey, Nancy Olsen

AU - Castronovo, Frank P.

AU - Mariani, Giuliano

AU - Black, Peter Mc L.

AU - Adelstein, S. James

PY - 1996/4/1

Y1 - 1996/4/1

N2 - We have initiated a study in which patients suspected of having primary gliomas are given a single intracerebral injection of the thymidine analog 5-[123I]iodo-2′-deoxyuridine ([123I]IUdR). The purpose of the study is to determine the biodistribution of the radiopharmaceutical and to calculate dose estimates to the tumor and normal tissues. Methods: A patient with a cystic glioma was injected with [123I]IUdR. Whole-body scans and brain scans were obtained at various times after injection, and blood, urine and stools were collected and assayed for radioactivity to assess its biodistribution and clearance. Results: Scintigraphic imaging demonstrated that the distribution of radiolabeled IUdR was mainly confined to the tumor (injection site), stomach and bladder. Disappearance from the tumor site and blood clearance were delayed probably due to collection in the cystic lesion. Eighty percent of the injected dose was recovered in the urine. Conclusion: The pharmacokinetics of [123I]IUdR locoregionally administered to a human glioma in situ resembled those observed in a rat glioma model where administration of the radiopharmaceutical radiolabeled with the Auger electron emitter 125I was therapeutically effective.

AB - We have initiated a study in which patients suspected of having primary gliomas are given a single intracerebral injection of the thymidine analog 5-[123I]iodo-2′-deoxyuridine ([123I]IUdR). The purpose of the study is to determine the biodistribution of the radiopharmaceutical and to calculate dose estimates to the tumor and normal tissues. Methods: A patient with a cystic glioma was injected with [123I]IUdR. Whole-body scans and brain scans were obtained at various times after injection, and blood, urine and stools were collected and assayed for radioactivity to assess its biodistribution and clearance. Results: Scintigraphic imaging demonstrated that the distribution of radiolabeled IUdR was mainly confined to the tumor (injection site), stomach and bladder. Disappearance from the tumor site and blood clearance were delayed probably due to collection in the cystic lesion. Eighty percent of the injected dose was recovered in the urine. Conclusion: The pharmacokinetics of [123I]IUdR locoregionally administered to a human glioma in situ resembled those observed in a rat glioma model where administration of the radiopharmaceutical radiolabeled with the Auger electron emitter 125I was therapeutically effective.

KW - Central nervous system tumors

KW - Intratumoral injection

KW - Iodine-123-IUdR

UR - http://www.scopus.com/inward/record.url?scp=0030116196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030116196&partnerID=8YFLogxK

M3 - Article

C2 - 8676198

AN - SCOPUS:0030116196

VL - 37

SP - 19S-22S

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 4 SUPPL.

ER -